Welcome to our dedicated page for ARCELLX news (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on ARCELLX stock.
Arcellx Inc. (ACLX) is a clinical-stage biotechnology company pioneering controllable cell therapies for cancer and complex diseases. This page aggregates official press releases and verified news about ACLX's immunotherapy advancements, clinical trial progress, and regulatory developments.
Investors and researchers will find timely updates on key milestones including trial results, partnership announcements, and FDA communications. Our curated collection spans therapeutic innovations in multiple myeloma, acute myeloid leukemia, and emerging cell therapy platforms.
All content is sourced directly from company filings and reputable financial publications. Bookmark this page for centralized access to ACLX's latest scientific breakthroughs and strategic business decisions in the evolving cell therapy landscape.
Arcellx, Inc. (NASDAQ: ACLX) initiated a Phase 1 clinical trial for ACLX-001 utilizing its innovative ARC-SparX technology to treat relapsed or refractory multiple myeloma (r/r MM). The company raised $142 million in its IPO and reported cash reserves of $210.9 million as of March 31, 2022, sufficient to fund operations into late 2023. Unfortunately, they posted a net loss of $32.4 million with R&D expenses increasing to $24.4 million. Upcoming presentations at the ASCO Annual Meeting are anticipated to provide further insights into their clinical data.
Arcellx, Inc. (NASDAQ: ACLX) has initiated its Phase 1 clinical trial for ACLX-001, targeting relapsed or refractory multiple myeloma (r/r MM). The trial, utilizing the innovative ARC-SparX platform, aims to evaluate safety and tolerability while addressing challenges like dose-limiting toxicities and tumor heterogeneity. The first patient has been dosed, and initial data is expected in 2023. The ARC-SparX technology combines SparX proteins and ARC-T cells to enable controlled and adaptable treatment options, potentially enhancing patient access to CAR-T therapies.
On May 9, 2022, Arcellx, Inc. (ACLX) announced key clinical data for CART-ddBCMA from its ongoing Phase 1 study aimed at treating relapsed or refractory multiple myeloma. Published in Blood Advances, the findings show a 100% overall response rate (ORR) and a 75% complete response/sustained complete response (CR/sCR) in 12 patients. The trial reported no significant adverse effects, solidifying CART-ddBCMA's safety profile. Following these results, Arcellx plans to expand the study and present new data at ASCO on June 5, with a pivotal Phase 2 study expected later in 2022.
Arcellx, Inc. (NASDAQ: ACLX) will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 5:00 p.m. E.T. The discussion will be accessible via a live webcast on the company's website and will be archived for 30 days. Arcellx focuses on developing advanced immunotherapies for cancer and other diseases, with its lead candidate CART-ddBCMA currently in a Phase 1 study for relapsed or refractory multiple myeloma. The company holds multiple designations from the FDA to expedite its clinical development.
Arcellx, Inc. (NASDAQ: ACLX) announced the upcoming presentation of new clinical data from its Phase 1 Study of CART-ddBCMA for treating relapsed or refractory multiple myeloma at the ASCO Annual Meeting on June 5, 2022. The oral presentation will be delivered by Dr. Matthew J. Frigault from Massachusetts General Cancer Center. The company will also host a live webcast discussing these results on the same day. CART-ddBCMA has received Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations from the FDA, underscoring its potential in cell therapy.
Arcellx (ACLX) announced promising preclinical data for ACLX-002, a CD123-targeted universal CAR-T cell therapy aimed at treating relapsed or refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The data show complete regression of multiple AML xenografts, evidencing the therapy's potential effectiveness. The company plans to initiate a Phase 1 clinical trial for ACLX-002 in the second half of 2022. The findings were presented at the AACR Annual Meeting, highlighting the innovative ARC-SparX platform that aims to improve treatment options for patients.
Arcellx, Inc. (NASDAQ: ACLX) raised $142.3 million via its upsized IPO, completed in February 2022, enhancing its ability to advance innovative therapies for cancer. The company reported a net loss of $65 million for 2021, up from $32 million in 2020. R&D expenses rose significantly to $46.9 million for the year, driven by developments in its CART-ddBCMA program. Arcellx plans to progress its CART-ddBCMA program to Phase 2 and initiate two Phase 1 trials in 2022.
Arcellx, Inc. (NASDAQ: ACLX) announced participation by CEO Rami Elghandour and CMO Chris Heery in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 4:50 p.m. E.T. The discussion will be accessible via a live webcast on Arcellx's website, with a replay available for 30 days post-event. The company is focused on advancing cell therapies, particularly CART-ddBCMA for relapsed or refractory multiple myeloma, and is progressing ARC-SparX for acute myeloid leukemia. Both product candidates have received various FDA designations.
Arcellx, Inc. (NASDAQ: ACLX) announced the presentation of pre-clinical data for ACLX-002, a CD123-targeted CAR-T cell therapy aimed at treating relapsed or refractory Acute Myeloid Leukemia (AML), at the American Association for Cancer Research Annual Meeting 2022. ACLX-002 offers controllability through a dose-dependent activation mechanism, addressing patient-specific disease variations and reducing the risk of adverse events. The presentation is scheduled for April 10, 2022, at the New Orleans Convention Center, highlighting the company's commitment to advancing innovative cancer therapies.
Arcellx, Inc. (NASDAQ: ACLX) successfully closed its initial public offering, selling 9,487,500 shares of common stock at a public offering price of $15.00 per share, generating aggregate gross proceeds of $142.3 million. The offering included an additional 1,237,500 shares purchased by underwriters. The stock began trading on the Nasdaq Global Select Market on February 4, 2022. The offering was managed by BofA Securities, SVB Leerink, Barclays, and William Blair, with a registration statement filed with the SEC becoming effective on February 3, 2022.
